MedTrace Logo

Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2025-05-25

No results posted yet for this study

Summary

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Conditions

Interventions

BIOLOGICAL

ST-920

No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.

Sponsors & Collaborators

  • Sangamo Therapeutics

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Sangamo Therapeutics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-16
Primary Completion
2029-03-31
Completion
2039-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05039866 on ClinicalTrials.gov